---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000062"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:07:43.566367+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours

## Summary
- SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.
- By Day 10, response rate improved to 84.2% and remission to 63.2% in adults with major depressive disorder.
- Company notes positive early data; continues development and discussions with potential partners for Sunseeker asset.

## SEC filing metadata
- accession: 0001356576-24-000062
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/0001356576-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/supn-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000062
- JSON: https://secwatch.observer/filing/0001356576-24-000062.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.